Concepts (145)
Concepts are derived automatically from a person's publications.
Concepts are listed by decreasing relevance which is based on many factors, including how many publications the person wrote about that topic, how long ago those publications were written, and how many publications other people have written on that same topic.
| Name |
Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
|---|
| Intraocular Pressure | 8 | 2021 | 144 | 0.590 |
Why?
|
| Glaucoma, Open-Angle | 5 | 2021 | 38 | 0.460 |
Why?
|
| Cloprostenol | 2 | 2009 | 4 | 0.390 |
Why?
|
| Prostaglandins F, Synthetic | 1 | 2009 | 3 | 0.330 |
Why?
|
| Prostaglandins, Synthetic | 1 | 2009 | 3 | 0.330 |
Why?
|
| Antihypertensive Agents | 2 | 2009 | 398 | 0.310 |
Why?
|
| Trabeculectomy | 3 | 2016 | 17 | 0.260 |
Why?
|
| Glaucoma | 3 | 2016 | 89 | 0.250 |
Why?
|
| Veterans | 3 | 2021 | 1733 | 0.230 |
Why?
|
| Ophthalmology | 2 | 2016 | 197 | 0.210 |
Why?
|
| Internship and Residency | 3 | 2016 | 1158 | 0.190 |
Why?
|
| Drug-Related Side Effects and Adverse Reactions | 1 | 2023 | 254 | 0.180 |
Why?
|
| Contact Lenses | 1 | 2020 | 40 | 0.180 |
Why?
|
| Diabetic Retinopathy | 1 | 2023 | 155 | 0.180 |
Why?
|
| Corneal Diseases | 1 | 2020 | 101 | 0.170 |
Why?
|
| Optic Neuritis | 3 | 2004 | 28 | 0.160 |
Why?
|
| Visually Impaired Persons | 1 | 2018 | 7 | 0.160 |
Why?
|
| Gout | 1 | 2021 | 146 | 0.150 |
Why?
|
| Reoperation | 3 | 2016 | 819 | 0.150 |
Why?
|
| Intraoperative Complications | 2 | 2016 | 175 | 0.150 |
Why?
|
| Timolol | 2 | 2009 | 8 | 0.140 |
Why?
|
| Accidental Falls | 1 | 2018 | 104 | 0.140 |
Why?
|
| Macular Degeneration | 1 | 2018 | 113 | 0.140 |
Why?
|
| Vision Disorders | 1 | 2018 | 210 | 0.140 |
Why?
|
| Visual Acuity | 5 | 2018 | 807 | 0.130 |
Why?
|
| Hospitals, Veterans | 3 | 2018 | 354 | 0.130 |
Why?
|
| Medical Staff, Hospital | 1 | 2016 | 92 | 0.130 |
Why?
|
| Lens Implantation, Intraocular | 2 | 2016 | 341 | 0.120 |
Why?
|
| Anterior Chamber | 1 | 2015 | 57 | 0.120 |
Why?
|
| Inpatients | 1 | 2018 | 464 | 0.120 |
Why?
|
| Filtering Surgery | 1 | 2013 | 5 | 0.110 |
Why?
|
| Silver | 1 | 2013 | 22 | 0.110 |
Why?
|
| Diabetes Mellitus, Type 2 | 1 | 2023 | 1230 | 0.110 |
Why?
|
| Surgically-Created Structures | 1 | 2013 | 5 | 0.110 |
Why?
|
| Metal Nanoparticles | 1 | 2013 | 42 | 0.110 |
Why?
|
| Cataract Extraction | 1 | 2015 | 210 | 0.100 |
Why?
|
| Phacoemulsification | 1 | 2016 | 236 | 0.100 |
Why?
|
| Anti-Infective Agents, Local | 1 | 2013 | 70 | 0.100 |
Why?
|
| Surgical Wound Dehiscence | 1 | 2013 | 51 | 0.100 |
Why?
|
| Multiple Sclerosis | 3 | 2004 | 335 | 0.100 |
Why?
|
| Travoprost | 2 | 2009 | 2 | 0.100 |
Why?
|
| Retrospective Studies | 8 | 2023 | 16039 | 0.090 |
Why?
|
| Ophthalmic Solutions | 2 | 2009 | 89 | 0.090 |
Why?
|
| Aged | 10 | 2020 | 19095 | 0.090 |
Why?
|
| Education, Medical, Graduate | 1 | 2015 | 507 | 0.090 |
Why?
|
| Aged, 80 and over | 5 | 2018 | 6372 | 0.090 |
Why?
|
| Middle Aged | 10 | 2023 | 25993 | 0.080 |
Why?
|
| Thiazines | 1 | 2009 | 2 | 0.080 |
Why?
|
| Hyperemia | 1 | 2009 | 25 | 0.080 |
Why?
|
| Carbonic Anhydrase Inhibitors | 1 | 2009 | 24 | 0.080 |
Why?
|
| Blindness | 1 | 2009 | 72 | 0.080 |
Why?
|
| Outpatient Clinics, Hospital | 1 | 2009 | 72 | 0.080 |
Why?
|
| Thiophenes | 1 | 2009 | 60 | 0.080 |
Why?
|
| Drug Administration Schedule | 1 | 2009 | 724 | 0.070 |
Why?
|
| Adrenergic beta-Antagonists | 1 | 2009 | 233 | 0.070 |
Why?
|
| Sulfonamides | 1 | 2009 | 259 | 0.070 |
Why?
|
| Postoperative Complications | 2 | 2016 | 3016 | 0.070 |
Why?
|
| Male | 14 | 2023 | 60080 | 0.070 |
Why?
|
| Prospective Studies | 5 | 2021 | 6027 | 0.070 |
Why?
|
| Female | 15 | 2023 | 65529 | 0.070 |
Why?
|
| Visual Fields | 2 | 2004 | 133 | 0.070 |
Why?
|
| Adult | 9 | 2020 | 29011 | 0.060 |
Why?
|
| Humans | 18 | 2023 | 123070 | 0.060 |
Why?
|
| Contrast Sensitivity | 1 | 2004 | 59 | 0.060 |
Why?
|
| Disability Evaluation | 1 | 2004 | 190 | 0.050 |
Why?
|
| Endothelial Growth Factors | 1 | 2023 | 49 | 0.050 |
Why?
|
| Bevacizumab | 1 | 2023 | 63 | 0.050 |
Why?
|
| Case-Control Studies | 2 | 2021 | 3239 | 0.050 |
Why?
|
| Primary Health Care | 1 | 2009 | 752 | 0.050 |
Why?
|
| Aspirin | 1 | 2004 | 224 | 0.050 |
Why?
|
| Ranibizumab | 1 | 2023 | 70 | 0.050 |
Why?
|
| Intravitreal Injections | 1 | 2023 | 144 | 0.050 |
Why?
|
| Administration, Topical | 2 | 2013 | 143 | 0.050 |
Why?
|
| Angiogenesis Inhibitors | 1 | 2023 | 207 | 0.050 |
Why?
|
| Treatment Outcome | 5 | 2020 | 12123 | 0.050 |
Why?
|
| Glucocorticoids | 1 | 2004 | 377 | 0.050 |
Why?
|
| Prosthesis Fitting | 1 | 2020 | 7 | 0.050 |
Why?
|
| Vascular Endothelial Growth Factor A | 1 | 2023 | 413 | 0.050 |
Why?
|
| Sclera | 1 | 2020 | 58 | 0.040 |
Why?
|
| Cornea | 1 | 2004 | 645 | 0.040 |
Why?
|
| Optic Chiasm | 1 | 1999 | 15 | 0.040 |
Why?
|
| Clinical Competence | 2 | 2016 | 973 | 0.040 |
Why?
|
| Sarcoidosis | 1 | 1999 | 61 | 0.040 |
Why?
|
| Pseudotumor Cerebri | 1 | 1999 | 58 | 0.040 |
Why?
|
| Papilledema | 1 | 1999 | 78 | 0.040 |
Why?
|
| Aging | 1 | 2004 | 1176 | 0.040 |
Why?
|
| Optic Nerve Diseases | 1 | 1999 | 88 | 0.040 |
Why?
|
| Ocular Hypertension | 2 | 2009 | 26 | 0.040 |
Why?
|
| Risk Factors | 3 | 2021 | 10016 | 0.030 |
Why?
|
| Drug Combinations | 2 | 2009 | 269 | 0.030 |
Why?
|
| Diagnostic Techniques, Ophthalmological | 2 | 2009 | 97 | 0.030 |
Why?
|
| Corneal Edema | 1 | 2015 | 14 | 0.030 |
Why?
|
| Cohort Studies | 3 | 2016 | 4703 | 0.030 |
Why?
|
| Operating Rooms | 1 | 2016 | 71 | 0.030 |
Why?
|
| Odds Ratio | 1 | 2018 | 1244 | 0.030 |
Why?
|
| Patient Outcome Assessment | 1 | 2016 | 93 | 0.030 |
Why?
|
| Operative Time | 1 | 2016 | 160 | 0.030 |
Why?
|
| Macular Edema | 1 | 2015 | 89 | 0.030 |
Why?
|
| Logistic Models | 1 | 2018 | 1798 | 0.030 |
Why?
|
| Kaplan-Meier Estimate | 1 | 2016 | 1004 | 0.030 |
Why?
|
| Blister | 1 | 2013 | 19 | 0.030 |
Why?
|
| Double-Blind Method | 2 | 2009 | 1590 | 0.030 |
Why?
|
| Mitomycin | 1 | 2013 | 49 | 0.030 |
Why?
|
| Antimetabolites | 1 | 2013 | 33 | 0.030 |
Why?
|
| Antibiotics, Antineoplastic | 1 | 2013 | 126 | 0.030 |
Why?
|
| Rabbits | 1 | 2013 | 709 | 0.030 |
Why?
|
| Analysis of Variance | 1 | 2013 | 1008 | 0.020 |
Why?
|
| Incidence | 1 | 2018 | 3044 | 0.020 |
Why?
|
| United States | 3 | 2018 | 10651 | 0.020 |
Why?
|
| Risk Assessment | 1 | 2018 | 3317 | 0.020 |
Why?
|
| Tonometry, Ocular | 1 | 2009 | 31 | 0.020 |
Why?
|
| Inflammation | 1 | 2015 | 1403 | 0.020 |
Why?
|
| Magnetic Resonance Imaging | 3 | 2004 | 3544 | 0.020 |
Why?
|
| Referral and Consultation | 1 | 2009 | 529 | 0.020 |
Why?
|
| Anatomy, Cross-Sectional | 1 | 2004 | 15 | 0.020 |
Why?
|
| Follow-Up Studies | 2 | 2004 | 5048 | 0.010 |
Why?
|
| Body Weights and Measures | 1 | 2004 | 41 | 0.010 |
Why?
|
| Safety | 1 | 2005 | 218 | 0.010 |
Why?
|
| Joint Diseases | 1 | 2004 | 33 | 0.010 |
Why?
|
| Vision Tests | 1 | 2004 | 37 | 0.010 |
Why?
|
| Methylprednisolone Hemisuccinate | 1 | 2003 | 5 | 0.010 |
Why?
|
| National Institutes of Health (U.S.) | 1 | 2004 | 133 | 0.010 |
Why?
|
| Health Status Indicators | 1 | 2004 | 120 | 0.010 |
Why?
|
| Disease Models, Animal | 1 | 2013 | 4286 | 0.010 |
Why?
|
| Prednisone | 1 | 2003 | 274 | 0.010 |
Why?
|
| Heart Rate | 1 | 2005 | 586 | 0.010 |
Why?
|
| Brain | 2 | 2004 | 2962 | 0.010 |
Why?
|
| Radiography | 1 | 2004 | 822 | 0.010 |
Why?
|
| Adolescent | 3 | 2004 | 19096 | 0.010 |
Why?
|
| Anti-Inflammatory Agents | 1 | 2003 | 280 | 0.010 |
Why?
|
| Acute Disease | 1 | 2003 | 1093 | 0.010 |
Why?
|
| Clinical Trials as Topic | 1 | 2004 | 1084 | 0.010 |
Why?
|
| Recurrence | 1 | 2004 | 1419 | 0.010 |
Why?
|
| Blood Pressure | 1 | 2005 | 1325 | 0.010 |
Why?
|
| Sex Factors | 1 | 2003 | 1261 | 0.010 |
Why?
|
| Disease Progression | 1 | 2004 | 2023 | 0.010 |
Why?
|
| Young Adult | 1 | 2009 | 8837 | 0.010 |
Why?
|
| Quality of Life | 1 | 2004 | 1928 | 0.010 |
Why?
|
| Surveys and Questionnaires | 1 | 2004 | 3666 | 0.010 |
Why?
|
| Diagnosis, Differential | 1 | 1999 | 1876 | 0.010 |
Why?
|
| Animals | 1 | 2013 | 33791 | 0.010 |
Why?
|
| Cardiovascular Diseases | 1 | 2004 | 1862 | 0.010 |
Why?
|
| Infant | 1 | 2004 | 12355 | 0.010 |
Why?
|
| Child, Preschool | 1 | 2004 | 13881 | 0.000 |
Why?
|
| Child | 1 | 2004 | 24226 | 0.000 |
Why?
|